Suppression of basic fibroblast growth factor‐induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase‐angiotensin‐dependent pathway in hamster sponge granulomas

Open Access
Publisher Website
Google Scholar
Abstract
We investigated the profound involvement of mast cell chymase, an alternative angiotensin II‐generating enzyme, in angiogenesis using a specific chymase inhibitor. We also studied the functional profiles of this novel inhibitor in basic fibroblast growth factor (bFGF)‐induced angiogenesis. In this study, angiogenesis was induced by daily injections of bFGF (0.3 μg site−1 day−1), angiotensin I (2 nmol site−1 day−1) or angiotensin II (2 nmol site−1 day−1) into sponges implanted to male hamsters subcutaneously for 7 days. Angiogenesis in the granulation tissue surrounding sponges was evaluated by measuring the haemoglobin (Hb) content and local blood flow as the parameters for angiogenesis. A chymase inhibitor, BCEAB (4‐[1‐{[bis‐(4‐methyl‐phenyl)‐methyl]‐carbamoyl}‐3‐(2‐ethoxy‐benzyl)‐4‐oxo‐azetidine‐2‐yloxy]‐benzoic acid), was simultaneously administered into the implanted sponges (2 or 5 nmol site−1 day−1, for 7 days) treated with bFGF and strongly suppressed the haemoglobin contents in sponge granulomas. In the studies using a laser doppler perfusion imager, BCEAB (5 nmol site−1 day−1) also attenuated the bFGF‐induced increase of local blood flow around the implanted sponge granuloma. In bFGF‐induced angiogenesis, chymase activity in sponge granulomas was substantially increased. It was also confirmed that the chymase activity increased by bFGF was significantly and dose‐dependently inhibited by BCEAB (2, 5 nmol site−1 day−1). BCEAB inhibited the Hb contents and the expression of vascular endothelial growth factor (VEGF) mRNA induced by angiotensin I but not by angiotensin II. These results suggest that the significance of chymase in bFGF‐induced angiogenesis was confirmed, and a novel inhibitor, BCEAB, strongly suppresses the bFGF‐induced angiogenesis through the chymase‐angiotensin II‐VEGF dependent pathway. British Journal of Pharmacology (2002) 137, 554–560. doi:10.1038/sj.bjp.0704893